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Background. Polysaccharide vaccines had been used to control African meningitis epidemics for >30 years but
with little or modest success, largely because of logistical problems in the implementation of reactive vaccination
campaigns that are begun after epidemics are under way. After the major group A meningococcal meningitis epi-
demics in 1996–1997 (250 000 cases and 25 000 deaths), African ministers of health declared the prevention of men-
ingitis a high priority and asked the World Health Organization (WHO) for help in developing better immunization
strategies to eliminate meningitis epidemics in Africa.
Methods. WHO accepted the challenge and created a project called Epidemic Meningitis Vaccines for Africa
(EVA) that served as an organizational framework for external consultants, PATH, the US Centers for Disease Con-
trol and Prevention (CDC), and the Bill & Melinda Gates Foundation (BMGF). Consultations were initiated with
major vaccine manufacturers. EVA commissioned a costing study/business plan for the development of new group A
or A/C conjugate vaccines and explored the feasibility of developing these products as a public–private partnership.
Representatives from African countries were consulted. They conﬁrmed that the development of conjugate vaccines
was a priority and provided information on preferred product characteristics. In parallel, a strategy for successful
introduction was also anticipated and discussed.
Results. The expert consultations recommended that a group A meningococcal conjugate vaccine be developed
and introduced into the African meningitis belt. The results of the costing study indicated that the “cost of goods” to
develop a group A – containing conjugate vaccine in the United States would be in the range of US$0.35–$1.35 per
dose, depending on composition (A vs A/C), number of doses/vials, and presentation. Following an invitation from
BMGF, a proposal was submitted in the spring of 2001.
Conclusions. In June 2001, BMGF awarded a grant of US$70 million to create the Meningitis Vaccine Project
(MVP) as a partnership between PATH and WHO, with the speciﬁc goal of developing an affordable MenA con-
jugate vaccine to eliminate MenA meningitis epidemics in Africa. EVA is an example of the use of WHO as an im-
portant convening instrument to facilitate new approaches to address major public health problems.
Keywords. meningitis epidemics; group A meningococcal conjugate vaccines; feasibility study; innovation; pub-
lic-private partnership.
The history of epidemic meningitis in sub-Saharan Afri-
can countries has been well documented [1]. Every year
from January to May when much of sub-Saharan Africa
is dry, windy, and dusty, epidemics of meningococcal
meningitis occur. Every 10–15 years, meningococcal ep-
idemics can assume major proportions such as the 1996
epidemic, which caused an estimated 250 000 cases with
>25 000 deaths [2].
Until the recent introduction of a monovalent
group A meningococcal conjugate vaccine, PsA-TT
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(MenAfriVac), group A Neisseria meningitidis accounted for
about 80%–85% of cases [3]. Meningitis is one of the most
feared diseases on the African continent. Meningitis epidemics
caused major disruptions of fragile national public health sys-
tems because of the severity of the illnesses and the geographic
unpredictability of where the epidemics would occur. In addi-
tion to a case fatality rate of about 10%, approximately 20% of
survivors suffer serious sequelae such as deafness, mental retar-
dation, and seizures.
Polysaccharide (PS) A/C vaccines had been available for 20
years, and their use in reactive campaigns that are begun in re-
sponse to epidemics was strongly encouraged by the World
Health Organization (WHO) [4, 5]. TheWHO International Co-
ordinating Group was created in 1997 to facilitate the acquisition
and shipment of meningitis vaccines to African countries during
meningitis epidemics. The International Coordinating Group
also facilitated development of national preparedness plans and
response through its technical partners and their networks.
There were, however, important logistical problems in imple-
mentation of this reactive strategy. Epidemics had to be detected
early and the etiologic agent identiﬁed. In the 1990s, basic mi-
crobiological capabilities were in short supply in sub-Saharan
countries, and there was often a delay between identiﬁcation
of an outbreak and determining the agent responsible for the
epidemic. Funds for vaccine purchases had to be mobilized,
and supplies of PS vaccines had to be identiﬁed, purchased,
and shipped to epidemic countries. Country resources had to
be in place so vaccines could be properly received, stored, and
distributed to epidemic areas where vaccinations were done.
Each of these steps took time, such that meningococcal PS vac-
cines were often given after the epidemics were over. The end
result was that most of the reactive campaigns yielded only mar-
ginal public health beneﬁt.
In addition, meningococcal group A/C PS vaccines were not
considered to be optimal products for routine vaccination pro-
grams. Group A/C PS vaccines were not recommended for chil-
dren <24 months of age and did not induce long-term memory.
The PS vaccines did not decrease colonization and would not be
expected to generate herd protection [5].
DEVELOPMENT OF THE EPIDEMIC MENINGITIS
VACCINES FOR AFRICA PROJECT
After the catastrophic 1996 epidemic, a meeting of 26 ministries
of health (MOH) from meningitis belt countries (Benin, Burki-
na Faso, Burundi, Cameroon, Central African Republic, Chad,
Côte d’Ivoire, Democratic Republic of Congo, Ethiopia,
Erithrea, Ghana, Guinea, Guinea-Bissau, Kenya, Mali, Maurita-
nia, Niger, Nigeria, Rwanda, Senegal, South Sudan, Sudan,
Tanzania, The Gambia, Togo, and Uganda) took place in Oua-
gadougou, Burkina Faso. MOH delegates recognized that
epidemic meningitis was a public health emergency and that
the interventions being used were inefﬁcient, so countries com-
mitted themselves to work with WHO and to shift their strate-
gies from epidemic response to epidemic preparedness [5].
WHO’s Immunization, Vaccines and Biologicals department
began addressing this challenge in 1997 and 1998 by supporting
in part the clinical development of the group A/C conjugate vac-
cines as well as reviewing with vaccine manufacturers their plans
for developing group A conjugate vaccines. In addition, there was
great hope that an effort to develop a group C meningococcal
conjugate vaccine might include a group A conjugate vaccine
as well, thus creating a potentially valuable product for African
meningitis belt countries. In the end, and disappointingly, it
was chosen to pursue the development of monovalent group C
conjugate vaccines. A group A–containing vaccine only for the
sub-Saharan countries was not considered a market driver.
In an effort to formalize the African meningitis vaccine work,
WHO created the Epidemic Meningitis Vaccines for Africa
(EVA) project, led by Teresa Aguado and Luis Jodar. They
sought help from Dan Granoff from the Children’s Hospital
Oakland Research Institute (California) and Nancy Messonier
from the US Centers for Disease Control and Prevention
(CDC) in Atlanta, Georgia. Together they worked to codify
the rationale and goals of the EVA project as follows:
1. To prevent and ultimately eliminate meningococcal epi-
demics in the African meningitis belt, a new vaccine should (1)
be immunogenic in infants and induce long-term protection in
all age groups and (2) decrease nasopharyngeal carriage and
transmission, thereby providing herd protection. Herd protection
was considered to be of particular value in preventing meningo-
coccal epidemics in the countries of the African meningitis belt
where infant immunization rates at that time were <50%.
2. Conjugate vaccines could eliminate meningococcal epi-
demics in the meningitis belt. Other conjugate vaccines had
been highly successful in preventing Haemophilus inﬂuenzae
type b (Hib) and pneumococcal infections. They were safe
and effective in infants and older children. Immunization also
decreased nasopharyngeal colonization and transmission of the
organism [6].The new conjugate vaccines showed great promise
because these vaccines initiated a T-cell response with height-
ened immunogenicity and could be used in toddlers aged <2
years, an age group in which polysaccharide vaccines are inef-
fectual. The meningococcal conjugate vaccines tested to that
date had similar immunologic properties as Hib and pneumo-
coccal conjugates and were predicted to be equally effective [7].
3. Group C meningococcal conjugate vaccines were licensed
in Europe and ﬁrst used in the United Kingdom in 1999 with-
out phase 3 efﬁcacy study, and had been introduced from in-
fants to young adults. Data indicated that these vaccines were
safe and highly effective in decreasing the incidence of group
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C disease in the United Kingdom [8]. Serum bactericidal anti-
bodies were a generally accepted surrogate of protection against
meningococcal disease. Therefore, the availability of a serologic
surrogate of efﬁcacy would provide a reliable early milestone for
assessing the likelihood of success of a meningococcal conjugate
vaccine for Africa.
4. Group A/C meningococcal conjugate vaccines had been
tested in African infants. In Niger, a WHO/CDC/Centre de Re-
cherche Médicale et Sanitaire project showed that these vaccines
were well tolerated and immunogenic, eliciting high titers of bac-
tericidal antibody [9]. In The Gambia, one conjugate vaccine
showed induction of immunologic memory for the C component,
important for long-term protection; however, the A component
behaved differently depending on the populations tested [10].
5. Intellectual property rights for the conjugation process
were in the public domain.
6. Technology and know-how were available from several
manufacturers and laboratories.
7. For more than a decade, several manufacturers had devel-
oped and clinically evaluated group A/C meningococcal conju-
gate vaccines. However, at the time of initiation of the EVA
project, all of these development programs had stopped. Possi-
ble reasons were:
• Lack of market potential. Group A meningococcus was vir-
tually nonexistent in industrialized countries, and disease
caused by this strain was limited to Africa and some areas in
the Eastern Mediterranean region and Asia.
• Research and development, clinical, and licensing costs were
not justiﬁed by the expected low return on investment. Oppor-
tunity costs were also cited—for example, that producing a vac-
cine of low commercial value could conﬂict with other projects
perceived to be more commercially valuable.
• Existing manufacturing capacity for conjugate vaccines was
insufﬁcient to cope with the required number of doses.
• Several manufacturers were in the process of producing ei-
ther group C or polyvalent vaccines for global use.
8. In addition, the timing for the development of new me-
ningococcal vaccines was perceived as appropriate. The Global
Alliance for Vaccines and Immunization (Gavi) had recently
been launched, and the Bill & Melinda Gates Foundation
(BMGF) and other partners were injecting new resources into
global health. Last, there was interest in stimulating the develop-
ment of needed vaccines in the developing world through new
pull-and-push mechanisms.
9. Finally, WHO believed that there was an opportunity to in-
volve a number of partners such as the CDC, Agence de Méde-
cine Préventive, Médecins Sans Frontières, and UNICEF with
speciﬁc expertise in epidemiology, vaccine evaluation, epidemic
control, and immunization program management. These part-
ners had already collaborated with WHO in speciﬁc projects,
and their expertise could contribute to the quality of the effort.
WHO, through the International Federation of Pharmaceuti-
cal Manufacturers and Associations, initiated discussions with 5
large international vaccine producers. Three manufacturers ex-
pressed interest in a possible future collaboration withWHO for
the development of a group A conjugate vaccine to be used in
Africa.
EVA commissioned a study that would explore manufactur-
ing costs to make a MenA conjugate vaccine. The proposal (a
business plan exploring different alternatives for public-private
partnerships for the development of a group A meningococcal
conjugate vaccine) described a not-for-proﬁt company (NFP)
for the development of a group A conjugate vaccine. The pro-
posal included 3 approaches for a public–private partnership:
(1) an alliance with a major vaccine company; (2) manufactur-
ing, in part, at the NFP; and (3) establishment of a full manu-
facturing facility at the NFP. Each of the options looked at
feasibility, resources required, timelines for licensure, and ulti-
mate costs of producing a group A or group A/C meningococcal
conjugate vaccine. The results of the exercise showed that a US
vaccine manufacturer making those vaccines at volumes of 25–
50 million doses annually could do so at a cost of US$0.35–
$1.35 per dose, depending on composition, number of doses/
vials, and type of formulation (liquid or lyophilized). The
model included ﬁnancing costs incurred in building a vaccine
manufacturing plant and a ﬁll/ﬁnish facility to package the vac-
cine. The facility was depreciated over 10 years, and clinical and
regulatory costs were also included. Therefore, if facilities and
ﬁll/ﬁnish lines were already available, a monovalent group A
conjugate vaccine could be made for as low as US$0.20 per
dose as long as annual volumes were >25 million doses.
This feasibility study provided EVA with a credible frame-
work for discussions with vaccine manufacturers when evaluat-
ing options in the creation of a public–private venture to
produce the vaccine. In addition, it provided a blueprint for al-
ternative public–private partnerships for other developing-
country market vaccines. Seed funding to support these and
other related activities was provided in part by the US Agency
for International Development.
An introduction plan for the new vaccine was also designed
and consisted of a routine immunization schedule for infants <1
year of age and mass immunization campaigns for those 1–29
years of age. Different immunization schedules were contem-
plated, and a phased introduction including a pilot effectiveness
study was also considered.
The EVA project was presented on 5–7 April 2000 at a WHO
meeting titled “Conjugate Vaccines Against Meningococcal
Disease in the African and Eastern Mediterranean Region,”
during which the 3 pillars of the project were presented and dis-
cussed: (1) business plan and feasibility study; (2) strategy for
introduction; and (3) ensuring appropriate advocacy and polit-
ical commitment. Following this consultation, an AFRO/EMRO
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(WHO’s regional ofﬁces in the African and Eastern Mediterra-
nean regions, respectively) statement was drafted that endorsed
the development of a new and affordable group A conjugate vac-
cine. The delegates made several recommendations, including (1)
giving priority to developing a group A vs an A/C conjugate vac-
cine; (2) indicating a preference for a single-dose schedule; (3) fa-
voring introduction through mass campaigns and into the
routine Expanded Programme on Immunization (EPI) schedule;
and (4) strengthening meningitis surveillance [11].
In June 2000, EVAwas asked to present its project to BMGF in
Seattle. The meeting compared and debated strategies to effectively
ﬁght the African meningitis epidemics. Experts vigorously debated
the advantages and constraints of expanding the use of the existing
PS vaccines vs a new group A or A/C meningococcal conjugate
vaccine aimed at eliminating epidemics in African countries.
DEVELOPMENT OF THE MENINGITIS VACCINE
PROJECT: A COLLABORATION BETWEEN WHO
AND PATH
For EVA’s ambitious goals to be realized, a core group with ex-
pertise in vaccine development and public–private partnerships
was needed. In July 2000, EVA initiated discussions with PATH,
a Seattle-based nongovernmental organization with technical,
legal, and operational experience in the development of needed
products for resource-poor countries. The PATH team was led
by Regina Rabinovich, who provided expertise and experience
in the creation of public–private partnerships that addressed
business as well as technical challenges. PATH and WHO
worked together on a product development plan that included
a private-sector vaccine producer partner, with technical sup-
port from key stakeholders such as the CDC. In addition, mul-
tiple meetings and consultations with a variety of experts were
held in which strategies were dissected.
In February 2001, a proposal was sent to BMGF requesting
funding for a 10-year project at the level of US$70 million. In
May 2001, WHO and PATH were informed that a US$70 mil-
lion grant was approved, and a public announcement was made
in Washington, D.C. by Patty Stonesifer, then the president of
BMGF, in the presence of representatives of both institutions.
EVA had now evolved into the Meningitis Vaccine Project
(MVP).
Key to the success of the collaboration was the conjunction of
several elements: (1) a sound project, with needs and solutions
clearly understood and supported by solid scientiﬁc evidence;
(2) an optimal combination of several partners with different
but complementary strengths; and (3) the ﬁnancial support at
a scope to make success possible. The grant provided core fund-
ing for the vaccine development through licensure and postli-
censure demonstration projects, with the understanding that
funds for vaccine purchases would be sought elsewhere.
DISCUSSION
The EVA project proved to be unique and effective in address-
ing an important public health problem. The following hall-
marks are worth noting:
1. It originated because of a pressing public health need that
had a sound rationale for resolving the problem.
2. Other conjugate vaccines had a proven record of success,
and more speciﬁcally, group C meningococcal conjugate vac-
cine introduction was proving to be highly effective in the Unit-
ed Kingdom.
3. The solutions proposed dealt in parallel with diverse is-
sues ranging from research and development through scaling
up and production, quality, supply, and ﬁnancing to large-
scale vaccine introduction at national level.
4. EVA anticipated the needs for a proper introduction in
sub-Saharan Africa, one of the most difﬁcult areas of the
world for the delivery of immunization programs. For example,
the need for signiﬁcantly improved meningitis surveillance in
the region was recognized as a priority.
5. The commissioned feasibility study provided the project
with a well-informed basis and a credible framework for discus-
sions with manufacturers.
6. From the outset, EVA solicited political commitment, sup-
port, and endorsement of the end users—the countries in need
of the vaccine—who requested not only the right product, but
an affordable one.
7. EVA, and subsequently MVP, offered a good model that
could be replicated for other developing country market vac-
cines [12]
8. The size of the award was commensurate with the funding
required for such an ambitious project. This allowed the project
team to drive the MVP development process without the inter-
ruption of continuously seeking funds for the core effort.
The EVA project involved a number of stakeholders, includ-
ing several WHO departments, meningitis experts, vaccine pro-
ducers, and public health institutions, some of whom continued
with MVP. EVA insisted on documentation and analysis on one
hand, and the projection of different scenarios to reach the goals
on the other. The PATH/WHO partnership resulted in great
complementarity.
EVA offered a venue for all agencies that were working on Af-
rican meningitis, where all ideas were considered in an open en-
vironment which, in the end, resulted in robust funding for MVP.
Eventually, MVP’s development work led to approaching a
broader group of vaccine manufacturers from developing coun-
tries who were interested in making a new meningococcal vac-
cine for Africa. Among these new manufacturers, the Serum
Institute of India, Ltd (SIIL) was selected in 2003 to manu-
facture the new vaccine that was licensed by Indian regulatory
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authorities in December 2009 and prequaliﬁed by WHO in
2010 [13, 14]. To date, approximately 210 million doses of
group A meningococcal conjugate vaccine manufactured by
SIIL, MenAfriVac, have been distributed in well-implemented
campaigns in the target countries.
The progression from WHO’s EVA to the MVP partnership
between PATH and WHO is a useful example of the key con-
vening role that WHO can play in serving as an organizing
locus to allow for creative discussions that led to the formulation
of a comprehensive solution to an important public health
problem. When considered in retrospect, it was an elegant ex-
ample of partnership: at the same time that WHO was key in
pulling partners together, PATH was key in the preparation of
a more comprehensive grant to BMGF through its understand-
ing and experience developing new products, while the CDC
and other partners provided technical expertise. Success in ob-
taining support from BMGF occurred because the foundation
recognized the quality of the partnership that was being pro-
posed. In the end, the scope of BMGF support offered the
newly created project, MVP, the opportunity to succeed.
EVA and MVP represented a big challenge, but they also of-
fered to all involved a unique opportunity to achieve major im-
pact with the resulting product, a new vaccine, and a model to
follow for other undertakings.
Notes
Acknowledgments. The Epidemic Meningitis Vaccines for Africa pro-
ject beneﬁted from the efforts of many individuals who generously contrib-
uted their time and expertise. We offer special thanks to Claire Broome,
formerly Deputy Director, US Centers for Disease Control and Prevention
(CDC); Arthur Elliot, consultant; Carl Frasch, US Food and Drug Admin-
istration; Ian Feavers, National Institute for Biological Standards and Con-
trol, UK; Ruth Frischer, formerly of the US Agency for International
Development; Sir Brian Greenwood, London School of Hygiene and Tropi-
cal Medicine, UK; Julie Milstein, formerly with World Health Organization
Immunization, Vaccines and Biologicals; Melinda Moree, formerly of
PATH; David Salisbury, former Director of Immunization at the Depart-
ment of Health, London, UK; and Nancy Messonnier, CDC Center for Sur-
veillance, Epidemiology, and Laboratory Services, Atlanta. Special thanks go
to F. Marc LaForce, former Meningitis Vaccine Project Director, for his crit-
ical review of the manuscript and his encouragement.
Disclaimers. 1) The authors and editors alone are responsible for the
views expressed in this publication and they do not necessarily represent
the views, decisions, or policies of the institutions with which they are afﬁl-
iated; 2) The designations employed and the presentation of the material in
this publication do not imply the expression of any opinion whatsoever on
the part of PATH or theWorld Health Organization (WHO) concerning the
legal status of any country, territory, city or area or of its authorities, or con-
cerning the delimitation of its frontiers or boundaries. Dotted and dashed
lines on maps represent approximate border lines for which there may not
yet be full agreement; 3) The mention of speciﬁc companies or of certain
manufacturers’ products does not imply that they are endorsed or
recommended by PATH or the WHO in preference to others of a similar
nature that are not mentioned. Errors and omissions excepted, the names
of proprietary products are distinguished by initial capital letters.
Supplement sponsorship. This article appears as part of the supplement
“The Meningitis Vaccine Project: The Development, Licensure, Introduc-
tion, and Impact of a New Group A Meningococcal Conjugate Vaccine
for Africa,” sponsored by the Meningitis Vaccine Project through a grant
from the Bill & Melinda Gates Foundation.
Potential conﬂicts of interest. All authors: No reported conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
References
1. Greenwood B. Manson lecture. Meningococcal meningitis in Africa.
Trans R Soc Trop Med Hyg 1999; 93:341–53.
2. World Health Organization. Epidemic meningitis in Africa, 1997. Wkly
Epidemiol Rec 1997; 72:313–5.
3. Campagne G, Schuchat A, Djibo S, Ousseini A, Cisse L, Chippaux JP.
Epidemiology of bacterial meningitis in Niamey, Niger, 1981–96. Bull
World Health Organ 1999; 77:499–508.
4. Miller MA, Wenger J, Rosenstein N, Perkins B. Evaluation of meningo-
coccal meningitis vaccination strategies for the meningitis belt in Africa.
Pediatr Infect Dis J 1999; 18:1051–9.
5. World Health Organization. Group A and C meningococcal vaccines,
WHO position paper. Wkly Epidemiol Rec 1999; 74:297–304.
6. Global Program for Vaccines and Immunization. Position paper on
Haemophilus inﬂuenzae type b conjugate vaccines. Wkly Epidemiol
Rec 1998; 73:64–71.
7. Advisory Committee on Immunization Practices (ACIP). Licensure of a
meningococcal conjugate vaccine for children aged 2 through 10 years
and updated booster dose guidance for adolescents and other persons at
increased risk for meningococcal disease. MMWR Morb Mortal Wkly
Rep 2011; 60:1018–9.
8. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated post-
licensure surveillance of the meningococcal C conjugate vaccine in
England and Wales: effectiveness, validation of serological correlates
of protection, and modeling predictions of the duration of herd immu-
nity. Clin Vaccine Immunol 2010; 17:840–7.
9. Campagne G, Garba G, Fabre P, et al. Safety and immunogenicity
of three doses of a Neisseria meningitidis A+C diphtheria con-
jugate vaccine in infants from Niger. Pedriatr Infect Dis J 2000;
19:144–50.
10. Twumasi PA, Kumah S, Leach A, et al. A trial of a group A plus group C
meningococcal polysaccharide-protein conjugate vaccine in African
infants. J Infect Dis 1995; 171:632–8.
11. World Health Organization meeting report. Joint recommendations for
the development and introduction of conjugate vaccines against menin-
gococcal disease in the African and Eastern Mediterranean regions—
annex to WHO meeting report, April 2000.
12. Jódar L, LaForce FM, Ceccarini C, Aguado T, Granoff DM. Meningo-
coccal conjugate vaccine for Africa: a model for development of new
vaccines for the poorest countries. Lancet 2003; 361:1902–4.
13. LaForce FM, Okwo-Bele JM. Eliminating epidemic group A meningo-
coccal meningitis in Africa through a new vaccine. Health Aff 2011;
30:1049–57.
14. Tiffay K, Jodar L, Kieny MP, Socquet M, LaForce FM. The evolution
of the meningitis vaccine project. Clin Infect Dis 2015; 61(suppl 5):
S396–403.
Meningitis in Africa • CID 2015:61 (Suppl 5) • S395
